# Mirdametinib in Histiocytic Disorders

Source: https://onco.cc/trials/nct06153173/  
OnCo record `nct06153173` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mirdametinib in Langerhans cell histiocytosis and Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, run by Children's Hospital Medical Center, Cincinnati, now recruiting.

## Summary

Mirdametinib in Histiocytic Disorders is a phase 2 interventional study registered as NCT06153173 by Children's Hospital Medical Center, Cincinnati, with 40 participants planned, started 2024-02-05 and due to reach its primary completion in 2030-03. Interventions recorded: Mirdametinib. Conditions recorded: Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders.

Linked to the drug Mirdametinib because the registry names it among its interventions and Langerhans cell histiocytosis and Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06153173
- Phase: 2
- Setting: A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders
- Sponsor: Children's Hospital Medical Center, Cincinnati
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06153173: https://clinicaltrials.gov/study/NCT06153173

## Connected records

- cancers: [Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms](https://onco.cc/cancers/histiocytoses/), [Langerhans cell histiocytosis (LCH)](https://onco.cc/cancers/langerhans-cell-histiocytosis/)
- drugs: [Mirdametinib](https://onco.cc/drugs/mirdametinib/)

---
JSON: https://onco.cc/api/v1/entities/nct06153173.json